RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental antibody takes aim at tough lymphoma
Disease control OngoingThis early-phase trial is testing an experimental antibody called MEDI-570 in 21 people with certain types of T-cell lymphoma that have come back or not responded to treatment. The goal is to find the safest dose and see how the body handles the drug. MEDI-570 works by targeting …
Matched conditions: RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug duo targets Hard-to-Treat lymphomas
Disease control OngoingThis early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Resea…
Matched conditions: RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Two-Drug attack on tough lymphoma shows promise in early trial
Disease control OngoingThis study tests whether combining two drugs—pembrolizumab (Keytruda), which helps the immune system fight cancer, and romidepsin (Istodax), which blocks cancer cell growth—can safely treat peripheral T-cell lymphoma that has returned or not responded to prior therapy. The trial …
Matched conditions: RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC